Convalescent plasma to treat COVID-19 | Blood | American Society of Hematology
In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transf
In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transf
Key Points. CAR-T cell therapy demonstrates superior efficacy to bispecific antibody in DLBCL treatment, with higher complete response rates.CAR-T cell the
Disclosures. Kean:Merck EMD Serono: Research Funding; Novartis: Research Funding; Tessera: Research Funding; Vertex: Consultancy, Membership on an entity’s
Blood | 143 | 18 | May 2024
New mouse model allows for side-by-side comparison of antitumor activity and side effects of immunotherapeutics targeting the same epitope.Immunotherapies
In publications on BTK and its inhibitors, phosphorylation of tyrosine 223 is often considered necessary for complete catalytic activity.We gene-edited mic
HSC increase autophagy in response to mitochondrial stress and cytokine stimulation with IL-1β and TNF identified as key inducers.HSC and HPC require autop
Clonal hematopoiesis (CH) occurs when somatic mutations confer a fitness advantage in blood cells enabling them to outcompete, increases with age, and has
Cappelli LV, Meggendorfer M, Baer C, . Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. Leukemia. 2021; doi: 10.1
Abstract. Myelodysplastic syndromes (MDS) can be difficult to diagnose, especially when morphological changes in blood and marrow cells are minimal, myeloblast
In this issue of Blood, Leung et al1 present preclinical findings demonstrating the potential of neoantigen-specific T cells to recognize acute myeloid leu